BioSensory SD A1cCare - Annex 1: Information for Healthcare Professionals; Protection against infections

To Next Page

To Previous Page

Annex 1: Information for Healthcare Professionals

Protection against infections

There is a potential risk of infection. Medical sta using SD A1cCare™ analyzer to perform

measurements for more than one patient must be aware that any object coming into

contact with human blood is a potential source of infection.

t Use gloves.

t Apply blood outside the analyzer. When measuring glucose in several persons clean

and disinfect the analyzer before each measurement as blood cannot be applied

using capillary pipettes.

t When measuring HbA1c in several persons, always use capillary pipettes to apply

blood outside the analyzer.

t Dispose of used capillary pipettes and test kits in a clinical waste bin.

t Follow all other locally applicable guidelines and regulations on health and safety.

Annex 2: References

1. (PMETUFJO%&-JUUMF33-PSFO[3".BMPOF+*/BUIBO%1FUFSTPO$.5FTUTPG

glycemia in diabetes. Diabetes Care 1995; 18:896-909.

2. Bunn HF. Nonenzymatic glycosylation of protein: relevance to diabetes. Am J Med

1981; 70:325-30.

3. +PWBOPWJD-1FUFSTPO$.5IFDMJOJDBMVUJMJUZPGHMZDPTZMBUFEIFNPHMPCJO"N+.FE

1981; 70:331-8.

4. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the

glycosylated hemoglobin assay. N EnglJ Med 1984; 310:341-6.

5. Brooks DE, Devine DV, Harris PC, et al. RAMP(TM): A rapid, quantitative whole blood

immunochromatographic platform for point-of-care testing.Clin Chem 1999;45:1676-

1678.

6. -JUUMF33FUBM3FMBUJPOTIJQPGHMZDPTZMBUFEIFNPHMPCJOUPPSBMHMVDPTFUPMFSBODF

Implications for diabetes screening. Diabetes 1988; 37(1):60-64.